Board of examiners

Prof. Dr. Richard Moriggl
Ludwig Boltzmann Institute for Cancer Research (LBI-CR)
University of Veterinary Medicine, Vienna, Austria

Prof. Dr. Kim De Keersmaecker
VIB Center for the Biology of Disease
KU Leuven

Prof. Dr. Johan Swinnen
Laboratory of Lipid Metabolism and Cancer
KU Leuven

Prof. Dr. Kris Thielemans
Department of Physiology and Immunology
VUB

Prof. Dr. Christian Demanet
HLA and Molecular Hematology Laboratory
UZ Brussel – VUB

Karin Vanderkerken, Chair
Department of Hematology and Immunology
VUB

Prof. Dr. Jacques De Grève, Promotor
Centre of Oncology
UZ Brussel – VUB

Prof. Dr. Joeri L. Aerts, Co-promotor
Department of Physiology and Immunology
VUB

Prof. Dr. Karine Breckpot, Co-promotor
Department of Physiology and Immunology
VUB

PhD in Medical Sciences
2016-2017

INVITATION to the Public defence of

Zhuo REN

To obtain the academic degree of 'DOCTOR IN MEDICAL SCIENCES'

The interrelationship between Nucleophosmin and STAT3/5 in cancer.

Monday 12 December 2016
Auditorium P. Brouwer, 16:00
Faculty of Medicine and Pharmacy, Laarbeeklaan 103, 1090 Brussel

How to reach the campus Jette:
http://www.vub.ac.be/english/infoabout/campuses
Summary of the dissertation

The development and progression of cancer require the concerted activation and participation of a pool of different oncogenic signal pathways. Some of these oncogenic pathways converge at a nuclear phosphoprotein named nucleophosmin (NPM). NPM transcriptionally regulates p53 gene, and stabilizes its expression. It is also an important ubiquitination target of BRCA1-BARD1 complex, where cancer predisposing mutations occur leading to development of hereditary breast cancer. Moreover, genetic mutations on NPM gene were found to be associated with haematological malignancies including acute myeloid leukemia (AML) and anaplastic large T cell lymphoma (ALCL). In the development of ALCL, fusion protein NPM-ALK drives transformation of CD4+ T cells by phosphorylating members of signal transducer and activator of transcription (STAT) family. However, little is known how wild type NPM interacts with the signal pathways mentioned above in cancers.

The present thesis dissected this fundamental question into three more specific questions: (1) whether wild type NPM is functionally related to STAT3 in cancers; (2) whether there is a potentially regulatory relationship between NPM and STAT5 in cancers; (3) whether there is any cancer predisposing mutation in NPM gene in breast cancers bearing no BRCA1/2 mutation.

The first section of the thesis demonstrated that tyrosine 705 phosphorylated STAT3 (P-STAT3) physically interacts with NPM, and transcriptionally regulates the expression level of NPM gene. The second section further explored the relationship between STAT5 and NPM in cancers, and unveiled that phosphorylated STAT5 regulates p53 expression via BRCA1/BRAD1-NPM1 and MDM2 in cancers. The third section identified a genetic variation, c.772-46 C>A, among 198 high risk breast cancer families in which BRCA1/2 mutation was found negative. Though this mutation is not cancer predisposing, its in vitro expression accelerate the turnover of NPM protein, leading to its destabilization.

Curriculum Vitae

Postdoctoral training
Princess Margaret Cancer Centre, University Health Network (UHN), Toronto
Ph.D. studies
Vrije Universiteit Brussel (VUB, Free University of Brussels), Brussels, Belgium
M.Sc. studies in Surgical Oncology
Shanghai Jiaotong University, Shanghai, China
Medical doctoral studies
Jiangxi Medical College, Nanchang University, Nanchang, China